Patents by Inventor Darrick Carter

Darrick Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine composition containing synthetic adjuvant
    Patent number: 8840908
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: September 23, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20140193459
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: May 3, 2013
    Publication date: July 10, 2014
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Compositions and methods for modulating the activity of complement regulatory proteins on target cells
    Patent number: 8753639
    Abstract: This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: June 17, 2014
    Assignees: University of Washington through its Center for Commercialization, Compliment Corporation
    Inventors: André Lieber, Hongjie Wang, Ronald Jay Berenson, Darrick Carter
  • Process and system for iontophoretic wrinkle reduction
    Patent number: 8747383
    Abstract: A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin of the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: June 10, 2014
    Assignee: University Medical Pharmaceuticals Corp.
    Inventors: Ray Francis, John Trengove, Greg Hunt, Josh Hoyt, Jim Thorne, Darrick Carter
  • Synthetic glucopyranosyl lipid adjuvants
    Patent number: 8722064
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 13, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20140037691
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: June 28, 2013
    Publication date: February 6, 2014
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20130084307
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 4, 2013
    Applicant: Infectious Disease Research Institute
    Inventors: STEVEN G. REED, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20130058997
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 7, 2013
    Applicant: Infectious Disease Research Institute
    Inventors: STEVEN G. REED, Darrick Carter
  • Treatment of allergic conditions using a composition containing synthetic adjuvant
    Patent number: 8343512
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: January 1, 2013
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Vaccine composition containing synthetic adjuvant
    Patent number: 8273361
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: September 25, 2012
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20120039994
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: October 20, 2011
    Publication date: February 16, 2012
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices
    Patent number: 8062783
    Abstract: Systems, devices, and methods for powering and/or controlling electrically powered devices. A power supply system is operable to provide a voltage across at the active and the counter electrode assemblies of a transdermal delivery device. The system includes a power source and a magnetic coupling element.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: November 22, 2011
    Assignee: TTI ellebeau, Inc.
    Inventors: Darrick Carter, Joshua K. Hoyt, James Thorne, Forrest Seitz
  • PROCESS AND SYSTEM FOR IONTOPHORETIC WRINKLE REDUCTION
    Publication number: 20110190724
    Abstract: A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin of the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.
    Type: Application
    Filed: December 16, 2010
    Publication date: August 4, 2011
    Applicant: UNIVERSITY MEDICAL PHARMACEUTICALS CORPORATION
    Inventors: Ray Francis, John Trengove, Greg Hunt, Josh Hoyt, Jim Thorne, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20110070290
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: July 26, 2010
    Publication date: March 24, 2011
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. Reed, Darrick Carter
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20110014274
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: July 26, 2010
    Publication date: January 20, 2011
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. Reed, Darrick Carter
  • SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS
    Publication number: 20100310602
    Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.
    Type: Application
    Filed: June 4, 2010
    Publication date: December 9, 2010
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Steven G. Reed, Darrick Carter
  • Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
    Patent number: 7848801
    Abstract: A transdermal delivery device to passively deliver active agents to a biological interface includes an active agent reservoir comprising a first active agent of a first polarity; an outer active agent membrane taking the form of an ion-exchange membrane of a second polarity, an interfacial layer having a plurality of freely diffusible monovalent co-ions of the first polarity and having a first side adjacent to the outer active agent membrane and a second side configured to contact a biological interface.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: December 7, 2010
    Assignee: TTI ellebeau, Inc.
    Inventors: Darrick Carter, Gregory A. Smith
  • COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF COMPLEMENT REGULATORY PROTEINS ON TARGET CELLS
    Publication number: 20100255011
    Abstract: This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 7, 2010
    Applicants: UNIVERSITY OF WASHINGTON, COMPLIMENT CORPORATION
    Inventors: André Lieber, Hongjie Wang, Ronald Jay Berenson, Darrick Carter
  • APPARATUS AND METHOD TO DISPENSE HPC-BASED VISCOUS LIQUIDS INTO POROUS SUBSTRATES, E.G., CONTINUOUS WEB-BASED PROCESS
    Publication number: 20100069877
    Abstract: Systems and methods are provided for dispensing compositions comprising sols, sol-forming compounds, or highly viscous compositions into porous substrates. In some embodiments, the porous substrates are elements of transdermal delivery devices. In some embodiments, the highly viscous compositions comprise alkylcellulose ethers, or derivatives thereof, in particular, hydroxypropyl cellulose. Such may be useful in continuous web-based manufacturing processes.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 18, 2010
    Inventors: Gregory A. Smith, Dale Kalamasz, Tyler D.J. Westcott, Robert P. Kinsey, Darrick Carter, Paul Sleath
  • Iontophoretic device and method of delivery of active agents to biological interface
    Patent number: 7574256
    Abstract: An iontophoresis device includes: an active electrode element operable to provide an electrical potential; an inner active agent reservoir comprising: a first compartment having a diluent; a second compartment having an active agent; and a polymer complex layer disposed between the first compartment and the second compartment, the polymer complex being formed by a first hydrophilic polymer and a second hydrophilic polymer via hydrogen bonding. The polymer complex is electrically responsive and disintegrates when an electrical field is applied.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: August 11, 2009
    Assignee: TTI ellebeau, Inc.
    Inventor: Darrick Carter